Streetbeat News

Regulatory

CDXC

ChromaDex has received Orphan Drug Designation from the FDA for its Nicotinamide Riboside Chloride for the treatment of Ataxia Telangiectasia.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:51 pm

TLT

UUP

U.S. manufacturing activity contracted more than expected in May, leading to a decline in Treasury yields and a weakening of the U.S. dollar. The iShares 20+ Year Treasury Bond ETF (TLT) rallied by 0.9%, while the Invesco DB USD Index Bullish Fund ETF (UUP) fell by 0.4%. Traders increased their bets on a September rate cut.

Portfolio Pulse from Piero Cingari

June 03, 2024 | 3:50 pm

DNLI

Denali Therapeutics shares are trading higher after the FDA selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics Pilot Program.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:49 pm

VALN

Valneva SE announced that the results of two Phase 2 clinical trials for its Lyme disease vaccine candidate, VLA15, have been published in 'The Lancet Infectious Diseases'. These trials, along with a third Phase 2 trial in pediatric participants, support the design of the current pivotal Phase 3 trial, VALOR.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:46 pm

MBOT

Microbot Medical Inc. (NASDAQ:MBOT) shares surged after receiving FDA approval to proceed with human clinical trials for its LIBERTY Endovascular Robotic Surgical System. The company has signed a clinical trial service agreement with a leading academic medical center and is completing biocompatibility tests. The stock saw heavy trading volume, significantly exceeding its 100-day average.

Portfolio Pulse from Erica Kollmann

June 03, 2024 | 3:36 pm

MBOT

Microbot Medical shares are trading higher following the company's announcement of receiving FDA approval to proceed with its pivotal human clinical trial.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:34 pm

TD

Fresh allegations have surfaced that a TD banker accepted bribes, expanding the scope of the DOJ probe to Florida. This development could have significant implications for TD's reputation and regulatory standing.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:34 pm

NDAQ

EU antitrust regulators are unlikely to seek feedback from rivals and users regarding EEX's proposed remedies for its deal with Nasdaq. The regulators likely view the remedies as insufficient and are expected to open an investigation into the deal. EEX could potentially avoid the investigation by offering more remedies in the coming days, according to sources.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:25 pm

GRTX

Galera Therapeutics Inc (NASDAQ:GRTX) shares plummeted by 34.8% to $0.14 after receiving a delisting notice from Nasdaq due to non-compliance with listing standards. Trading will be suspended on June 4, 2024, and the company plans to move to OTC Markets Group.

Portfolio Pulse from Henry Khederian

June 03, 2024 | 3:17 pm

GRTX

Galera Therapeutics shares are trading lower after the company announced it will be delisted by Nasdaq.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:16 pm